Skip to main content
    H

    Harmony Biosciences Holdings (HRMY)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $32.96
    -0.80 (-2.37%)

    Market Cap: $1.98B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Harmony Biosciences Holdings (HRMY) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Harmony Biosciences Holdings reported EPS of $0.81, below the $1.00 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    67%(16/24)
    Avg Surprise
    +58.45%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus$1.04
    Range$0.60 - $1.61
    14 analysts
    Revenue Consensus
    $287.49M
    Range$265.93M - $306.60M
    14 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus$0.82
    Range$0.71 - $0.95
    4 analysts
    EPS Revisions
    2
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$0.83-1.2%
    60d ago$0.83-1.2%
    30d ago$0.83-1.2%
    7d ago$0.85-3.3%
    Current$0.82
    Revenue Consensus
    $259.29M
    Range$245.80M - $277.60M
    4 analysts

    Next Report

    Analysts' consensus for the quarter ending Dec 31, 2026 is 82.5% above the $0.57 reported for the quarter ended Dec 31, 2025.

    HRMY's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    HRMY Earnings Call

    The latest HRMY earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 24 quarters below that had an estimate, HRMY beat 16 and missed 8. Revenue for the quarter ended Sep 30, 2026 was $268.92M, up 12.3% from $239.46M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.81$1.00N/A-19.00%Miss-25.0%23 up, 0 downNov 4, 2026$268.92M
    Jun 30, 2026$1.28$0.97N/A+31.96%Beat+39.1%31 up, 1 downAug 4, 2026$261.28M
    Mar 31, 2026$0.79$0.93$0.67 - $1.22-15.05%Miss+1.5%50 up, 2 downMay 7, 2026$215.39M
    Dec 31, 2025$0.57$0.86N/A-33.72%Miss-47.2%42 up, 0 downFeb 24, 2026$243.78M
    Sep 30, 2025$1.08$0.86$0.81 - $0.91+25.58%Beat+4.9%21 up, 0 downNov 4, 2025$239.46M
    Jun 30, 2025$0.92$0.96$0.85 - $1.11-4.17%Miss-12.4%42 up, 1 downAug 5, 2025$200.49M
    Mar 31, 2025$0.78$0.91$0.77 - $1.45-14.79%Miss-11.5%30 up, 1 downMay 6, 2025$184.73M
    Dec 31, 2024$1.08$0.82$0.77 - $0.90+31.71%Beat+140.0%41 up, 0 downFeb 25, 2025$201.27M
    Sep 30, 2024$1.03$0.88N/A+17.05%Beat+6.2%80 up, 1 downOct 29, 2024$186.04M
    Jun 30, 2024$1.05$0.12N/A+775.00%Beat+38.2%60 up, 2 downAug 6, 2024$172.81M
    Mar 31, 2024$0.88$0.69N/A+27.54%Beat+33.3%71 up, 1 downApr 30, 2024$154.62M
    Dec 31, 2023$0.45$0.48$0.04 - $0.83-6.25%Miss-43.0%81 up, 1 downFeb 22, 2024$168.41M
    Sep 30, 2023$0.97$0.81N/A+19.75%Beat+2.1%80 up, 1 downOct 31, 2023$160.27M
    Jun 30, 2023$0.76$0.74N/A+2.70%Beat+33.3%81 up, 1 downAug 1, 2023$134.22M
    Mar 31, 2023$0.66$0.56$0.38 - $0.58+17.86%Beat+29.4%80 up, 0 downMay 2, 2023$119.13M
    Dec 31, 2022$0.79$0.58$0.47 - $0.81+36.21%Beat+107.9%80 up, 0 downFeb 21, 2023$128.31M
    Sep 30, 2022$0.95$0.19-$0.04 - $0.44+400.00%BeatN/A70 up, 0 downNov 1, 2022$117.21M
    Jun 30, 2022$0.57$0.63N/A-9.52%Miss+137.5%70 up, 1 downAug 2, 2022$107.03M
    Mar 31, 2022$0.51$0.42N/A+21.43%Beat+34.2%72 up, 0 downMay 3, 2022$85.31M
    Dec 31, 2021$0.38$0.36$0.27 - $0.47+5.56%Beat+52.0%61 up, 1 downFeb 28, 2022$91.21M
    Sep 30, 2021-$0.17$0.52N/A-132.69%MissN/A5N/ANov 9, 2021$80.73M
    Jun 30, 2021$0.24$0.17$0.13 - $0.24+41.18%BeatN/A3N/AAug 10, 2021$73.82M
    Mar 31, 2021$0.38-$0.01-$0.05 - -$0.01N/AN/AN/A3N/AMay 11, 2021$59.67M
    Dec 31, 2020$0.25$0.09$0.05 - $0.16+177.78%BeatN/A3N/AMar 25, 2021$56.29M
    Sep 30, 2020-$0.14-$0.15-$0.15 - $0.12+6.67%BeatN/A3N/ANov 12, 2020$45.61M
    Jun 30, 2020-$2.93N/AN/AN/AN/AN/AN/AN/AAug 19, 2020$38.01M
    Last 26 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $3.35, down 17.1% from the year before. It was -$2.82 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$3.35-17.1%
    Dec 31, 2024$4.04+42.3%
    Dec 31, 2023$2.84N/A
    Dec 31, 2022$2.82+239.8%
    Dec 31, 2021$0.83N/A
    Dec 31, 2020-$2.82N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,300 words across 17 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,30217
    2026Q2Jun 30, 20268,18015
    2026Q1Mar 31, 20268,38616
    2025Q4Dec 31, 20257,62117
    2025Q3Sep 30, 20257,75016
    2025Q2Jun 30, 20256,71814
    2025Q1Mar 31, 20258,07614
    2024Q4Dec 31, 20247,89415

    2026Q3 Earnings Call

    Opening remarks

    Brennan Doyle Head of Investor Relations Thank you, operator. Good morning, everyone, and thank you for joining us today as we review Harmony Biosciences' third quarter 2026 financial results and provide a business update. Before we start, I encourage everyone to go to the investors section of our website to find the materials that accompany today's discussion. Our speakers on today's call are Dr. Jeffrey Dayno, President and CEO; Peter Anastasiou, Senior Executive Vice President, Chief Operating Officer, and incoming President and CEO; Adam Zaeske, Chief Commercial Officer; Dr. Kumar Budur, Chief Medical and Scientific Officer; and Steve Mollichella, Interim Principal Financial Officer. As a reminder, we will be making forward-looking statements today, which are based on our current expectations and beliefs. These statements are subject to risks and uncertainties. Our actual results may differ materially, and we undertake no obligation to update these statements even if circumstances change. We encourage you to consult the risk factors referenced in our SEC filings for additional details. I would now like to turn the call over to our CEO, Dr. Jeffrey Dayno. Jeff.

    Jeffrey Dayno CEO Thank you, Brennan. Good morning, everyone, and thank you for joining our call today. Before I get into the quarter, I first want to say a few words about the CEO transition we announced last month. I will be stepping down at the end of the year, and Peter Anastasiou, our Senior Executive Vice President and Chief Operating Officer, will succeed me as President and Chief Executive Officer effective January 1st, 2027. I am confident that Harmony is in very good hands with Peter, and you will hear from him next. The main themes regarding the CEO transition are continuity, strength, and growth. This leadership transition does not signal any change in our overall business or our strategic priorities. We are doing this from a position of strength and executing a well-coordinated plan. Harmony continues to be a growth story, and during Q3, we moved that story forward in each of our four priorities of value creation: continue to grow WAKIX in an evolving market, advance a novel and robust clinical-stage pipeline, transact on strategic business development deals, and protect the pitolisant franchise. I will provide some more color on our first two strategic priorities of value creation and then turn it over to Peter to expand on our other two strategic priorities. The key highlights that I want you to take away from today's call are sustained patient demand-driven growth for WAKIX in its seventh year on the market, keeping us firmly on track to exceed $1 billion in net revenue this year, and preliminary multiple ascending dose data for our orexin-2 agonist, BP-205, that further strengthen its emerging best-in-class profile.

    Frequently Asked Questions About HRMY

    Did HRMY beat earnings estimates last quarter?

    No. Harmony Biosciences Holdings reported EPS of $0.81 for the quarter ended Sep 30, 2026, below the $1.00 estimate by 19.00%.

    What EPS do analysts expect from HRMY next quarter?

    The consensus EPS estimate for Harmony Biosciences Holdings for the quarter ending Dec 31, 2026 is $1.04 from 14 analysts, with estimates from $0.60 to $1.61.

    How often does HRMY beat earnings estimates?

    Harmony Biosciences Holdings beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of +0.31%.